Egypt vs Madagascar: HIV/AIDS deaths averted by antiretroviral therapy
Egypt
2,035 deaths
in 2024
Madagascar
2,165 deaths
in 2024
Egypt rank
56th
Madagascar rank
55th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Egypt
- Madagascar
How they compare
Madagascar currently reports 2,165 deaths against 2,035 deaths in Egypt, a difference of 130 deaths.
That makes Madagascar's figure about 1.1 times Egypt's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Madagascar ahead.
Egypt ranks 56th and Madagascar ranks 55th of 157 countries.
Egypt has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Egypt | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 23.89 deaths | 14.82 deaths | 9.07 deaths | Egypt |
| 2010s | 346.74 deaths | 196.24 deaths | 150.51 deaths | Egypt |
| 2020s | 1,477 deaths | 1,309 deaths | 168.29 deaths | Egypt |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Egypt or Madagascar?
- Madagascar, at 2,165 deaths against 2,035 deaths in Egypt as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Egypt and Madagascar?
- 130 deaths, with Madagascar ahead.
- How many years of comparable data are there for Egypt and Madagascar?
- 35 years are reported by both, from 1990 to 2024.
- How do Egypt and Madagascar rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Egypt ranks 56th and Madagascar ranks 55th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.